ESG vs GLP-1 (Semaglutide and Tirzepatide): The Head-to-Head Evidence

You have two very different ways to lose roughly the same amount of weight: a one-time incisionless procedure or a weekly injection you take indefinitely. Endoscopic sleeve gastroplasty (ESG) stitches the stomach into a narrow tube through the mouth and produced 13.6% total body weight loss at one year in the randomized MERIT trial^[1] — pooled around 15–17%^[2] and holding near 15.9% at five years^[3]. A GLP-1 works from the other direction: semaglutide (Wegovy) delivered −14.9% in STEP-1^[4] and tirzepatide (Zepbound) −20.9% in SURMOUNT-1^[5] — but only for as long as you keep injecting. There is no head-to-head randomized trial, so this is an honest cross-trial comparison across efficacy, durability, cost over time, invasiveness and risk, who each suits, and the combination approach that can beat either alone^[6]. No false winner — just the framework to decide.

The honest summary

• On raw weight loss, it's roughly a three-way split. ESG (~13.6–16%^[1][3]) is about level with semaglutide (~14.9%^[4]) and clearly below tirzepatide (~20.9%^[5]). If maximum weight loss is the only goal, tirzepatide leads.
• The real dividing line is one-time procedure vs ongoing drug. ESG is a single intervention with no monthly cost and no injections; its restriction persists. A GLP-1's weight loss lasts only as long as you keep taking it and tends to reverse after stopping.
• Durability favors ESG's staying power, drugs favor flexibility. ESG holds near 16% at five years^[3] with no ongoing action required; a GLP-1 can be titrated, paused, or switched, but weight comes back if it's discontinued.
• Cost math flips over time. ESG is a large one-time out-of-pocket cost with no recurring bill; a GLP-1 is a recurring monthly cost, sometimes partly insured. Over several years the cumulative drug spend can exceed the one-time procedure.
• Invasiveness and risk run opposite ways. A GLP-1 is non-invasive but comes with GI side effects; ESG is an endoscopic procedure under sedation with ~2% serious adverse events^[2] and a few days of recovery, but nothing ongoing.
• They aren't mutually exclusive. ESG plus liraglutide beat ESG alone in a randomized study^[6] — a “procedure plus medication” strategy that can capture more weight loss than either route by itself.

Efficacy: what the numbers actually say

The strongest single data point for ESG is the MERIT randomized controlled trial (Abu Dayyeh 2022, Lancet^[1]): 209 adults with class 1–2 obesity, 13.6% TBWL at 52 weeks with ESG versus 0.8% for lifestyle alone, and 77% of ESG patients reaching at least 25% excess weight loss. Meta-analysis (Hedjoudje 2020^[2]) pools 1,772 patients to 15–17% TBWL across the first two years, and the five-year cohort (Sharaiha 2021^[3]) reports 15.9% maintained at 5 years. On the drug side, the pivotal trials are just as clean:

• ESG ≈ semaglutide. If your target is ~15% TBWL, ESG^[1] and semaglutide^[4] arrive at a similar place by opposite routes — a procedure vs a weekly injection.
• Tirzepatide is the efficacy leader. At ~20.9%^[5], the dual GIP/GLP-1 agonist out-loses ESG on magnitude; no procedure short of surgery matches it.
• Every comparison here is cross-trial. No RCT has ever randomized patients to ESG vs a GLP-1, so treat these as directional reference points, not a decided contest.

Durability: persistence vs dependence

This is where the two diverge most sharply. ESG's mechanism — a physically smaller, slower-emptying stomach — persists without any ongoing action: MERIT showed 68% of ESG patients still holding at least 25% excess weight loss at 104 weeks^[1], and the five-year cohort maintained 15.9% TBWL^[3]. A GLP-1's effect, by contrast, is pharmacologically dependent: it works while the drug is in your system and its weight loss tends to reverse substantially after stopping, which is why it is framed as a chronic-disease medication rather than a course. The practical read: ESG is more forgiving if life interrupts treatment, while a GLP-1 offers the flexibility to titrate, pause, or switch — at the price of regain when discontinued. Behavior change still matters for both; ESG restricts the stomach but does not do the eating for you.

Cost economics over time

The cost comparison depends entirely on your time horizon. ESG is a large one-time out-of-pocket cost (in the US typically quoted around $8,000–$20,000) with no recurring drug bill — most insurers still classify it as investigational. A GLP-1 is a recurring monthly cost that may be partly insured but continues indefinitely, since stopping tends to reverse the weight loss. Over a single year a GLP-1 can look cheaper; over several years the cumulative injection spend can exceed the one-time procedure. Run your own numbers over a realistic horizon and factor in whether your insurance covers the drug — see how much weight-loss procedures cost. (Cost figures here are current US market ranges, not trial-derived.)

Prefer the GLP-1 route? Top vetted providers

Invasiveness and risk

• GLP-1 — non-invasive, but with side effects. A weekly self-injection, no procedure, no sedation. The trade-off is common gastrointestinal side effects (nausea, vomiting, constipation), especially during dose escalation, plus the need to manage a chronic prescription.
• ESG — a procedure, but a one-time one. Done under sedation in about 60–90 minutes, usually outpatient. Serious adverse events run about 2% (Hedjoudje 2020^[2]; 3 of 131 in MERIT^[1]) — mainly GI bleeding and peri-gastric fluid collections — with no deaths in the major series and 1.3% moderate events in the five-year cohort^[3]. Expect a few days of abdominal pain and nausea, then normal activity within about a week.
• Reversibility differs in kind. A GLP-1 is “reversible” by stopping — but so is its benefit. ESG places sutures rather than removing tissue, so it is largely reversible or revisable, and it preserves the option of a future surgical sleeve or bypass.

Who each option suits

• ESG fits adults with class 1–2 obesity (BMI ~30–40, the MERIT population^[1]) who want a durable, one-time, incisionless intervention without a lifelong prescription, who have not tolerated or succeeded with GLP-1s, or who cannot access or afford them long-term — and who are willing to pay out of pocket and keep up behavior change.
• A GLP-1 fits people who prefer a non-invasive option, want the largest medical weight loss (tirzepatide^[5]), value the flexibility to titrate or stop, or have at least partial insurance coverage — and who accept an ongoing prescription and regain risk if it's discontinued.
• The combination fits people who want more than either delivers alone, or who plateau on one route: ESG plus a GLP-1 captured more weight loss than ESG alone in a randomized study of ESG plus liraglutide^[6].

The combination approach

The framing “procedure or drug” is a false binary. In a randomized study, ESG plus liraglutide produced more weight loss than ESG alone (Badurdeen 2021^[6]) — the procedure supplies durable mechanical restriction while the drug adds pharmacologic appetite suppression on top. This mirrors how obesity is increasingly treated: stack complementary mechanisms rather than betting on one. It also offers a practical sequence — use ESG for a durable baseline, then add or cycle a GLP-1 when extra loss is needed or a plateau hits. How ESG combines with the newer, more potent GLP-1/GIP drugs (semaglutide, tirzepatide) has not yet been established in large trials, so this is a promising direction rather than a settled protocol.

A verdict framework (not a false winner)

• Want the largest weight loss? Tirzepatide leads on magnitude (~20.9%^[5]); ESG and semaglutide are a tier below and roughly level^[1][4].
• Want a one-time intervention with no monthly cost or injections? ESG — its effect persists for years without ongoing action^[3].
• Want non-invasive and reversible-by-stopping, with possible insurance help? A GLP-1 — accepting that the weight returns if you stop.
• Optimizing multi-year cost? Compare a one-time procedure against cumulative monthly drug spend over your real horizon; the answer depends on coverage and duration.
• Want the most weight loss achievable short of surgery? Consider the combination^[6] — or read the broader surgery vs GLP-1 picture and the decision guide.

Bottom line

• ESG (~13.6–16% TBWL^[1][3]) is about level with semaglutide (~14.9%^[4]) and below tirzepatide (~20.9%^[5]) — but no head-to-head trial exists, so these are cross-trial numbers.
• ESG's defining advantage is being a one-time, no-injection, potentially reversible procedure with no monthly cost and durable results; a GLP-1's advantages are being non-invasive, flexible, often partly insured, and (for tirzepatide) higher-magnitude.
• A GLP-1's weight loss reverses after stopping; ESG's restriction persists — but ESG carries a ~2% serious-complication risk^[2] and is usually out of pocket.
• Cost depends on horizon: one-time procedure vs recurring drug spend. Suitability depends on BMI, tolerance, coverage, and how you value invasiveness vs an ongoing prescription.
• They can be combined for more weight loss than either alone^[6] — this is not strictly an either/or choice.

Related research

• Endoscopic sleeve gastroplasty (ESG): the full evidence — how ESG works, safety, cost, and reversibility in depth
• Endoscopic (non-surgical) weight-loss options overview — the pillar map of ESG, balloons, and more
• Gastric balloon vs GLP-1 — the other endoscopic-vs-drug head-to-head
• ESG vs surgical sleeve gastrectomy — endoscopic vs surgical restriction
• Bariatric surgery vs GLP-1s — the surgery-vs-drug comparison
• Bariatric surgery vs GLP-1: the decision guide — choosing across all options
• GLP-1s after bariatric surgery for weight regain — the procedure-plus-medication approach in practice
• How much is weight-loss surgery? — the cost math ESG competes on

Important disclaimer. This article is educational and does not constitute medical advice. Endoscopic sleeve gastroplasty is an invasive procedure with real risks, and GLP-1 drugs are prescription medications with side effects; suitability for either depends on your BMI, health, and goals, and must be assessed by a qualified bariatric endoscopist or obesity-medicine physician. The ESG-vs-GLP-1 comparison here is cross-trial, not head-to-head, and should be interpreted with care. Cost figures are current US market ranges, not trial-derived. Do not start, stop, or change any treatment based on this article. PMIDs were independently verified against the PubMed E-utilities API on 2026-07-01.

Last verified: 2026-07-01. Next review: every 12 months, or sooner if a head-to-head ESG-vs-GLP-1 trial or a major long-term outcome study is published.